Market Overview

The Shenzhen‑listed ChemPartner Pharmatech (300149.SZ) closed the latest trading session unchanged, with a 0 % movement over a 24‑hour period that concluded at 11:00 AM Central Europe on Thursday, 22 September. The current trading price stands at CNY 8.08, with a circulating supply of 497.6 million shares. The company’s market capitalisation is CNY 4.1 billion, and the aggregate value of shares exchanged over the last 24 hours totals CNY 136.2 million.

In the broader context of the Chinese equity market, ChemPartner Pharmatech has slipped 16.83 % since the end of last month. Its 200‑day simple moving average sits at CNY 9.20. The 52‑week high, reached on 13 January 2026, was CNY 14.23, while the 52‑week low, recorded on 22 June 2026, was CNY 7.22.

Comparative Peer Activity

The short‑term performance of related equities provides a useful benchmark for ChemPartner Pharmatech:

  • Binjiang Service Ltd. (3316.HK) advanced 0.86 % to HKD 20.58, backed by a market cap of HKD 5.8 billion and a price‑to‑earnings ratio of 7.96.
  • Jinxi Axle (600495.SS) remained flat at CNY 4.13, with a market cap of CNY 4.9 billion and an earnings multiple of 145.71.
  • Haining China Leather Mar (002344.SZ) also traded sideways at CNY 3.81; its market cap is CNY 5 billion and its P/E stands at 54.53.
  • Nanxing Machinery (002757.SZ) held steady at CNY 16.85, supported by a market cap of CNY 5 billion and a P/E ratio of 36.31.
  • Hygeia Healthcare C (6078.HK) dropped 2.44 % to HKD 9.1, with a market cap of HKD 5.8 billion and a P/E of 28.06.

These peers exhibit a mix of modest gains, flat performance, and slight declines, reflecting a broader market that remains cautious amid macro‑economic uncertainties.

Company Snapshot

ChemPartner Pharmatech Co. Ltd. has carved a niche in the global prebiotic market. Founded in 2000 and headquartered in Guangzhou, the company specialises in the research, development, production, and commercialisation of prebiotic ingredients. Its flagship lines—fructooligosaccharides (EUOLIGO) and galactooligosaccharides (GOSYAN)—are incorporated into a diverse range of food and nutraceutical products, from infant formula and dairy to baked goods and beverages. With a listing on the Shenzhen Stock Exchange and an IPO date of December 22 2010, ChemPartner Pharmatech has steadily expanded its production footprint and market reach.

Forward‑Looking Assessment

Given the current flat trading trajectory, ChemPartner Pharmatech’s valuation appears to be stabilising around its 200‑day SMA. The 52‑week range indicates that the stock still has upside potential, particularly if the prebiotic sector continues to receive regulatory support and consumer demand for gut‑health products rises. The company’s focus on high‑margin ingredients, coupled with its established brand presence in key categories, positions it favourably to capture incremental market share in both domestic and international markets.

In a market environment where peers show mixed performance, ChemPartner Pharmatech’s resilience—evidenced by its steady pricing and sizeable trading volume—suggests that it is well‑aligned with investor expectations for steady growth. Should macro‑economic conditions improve, or should the company execute on its expansion plans, we anticipate a re‑ascendancy that could bring the stock back in line with its upper 52‑week ceiling.